Zura Bio Ltd Dossier
Qualitative Analysis
Business overview
Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases with high unmet medical needs. The company's approach focuses on dual-pathway biology, representing a potential paradigm shift for patients underserved by single-pathway medicines. Zura Bio's pipeline includes three clinical-stage product candidates: its lead asset tibulizumab (ZB-106), a potential first- and only-in-class bispecific antibody targeting the interleukin-17A (IL-17A) and B-cell activating factor (BAFF) pathways; crebankitug (ZB-168), an anti-IL-7Rα monoclonal antibody; and torudokimab (ZB-880), an anti-IL-33 monoclonal antibody.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead bispecific antibody candidate, tibulizumab (ZB-106), which targets both IL-17A and BAFF, through Phase 2 clinical trials (TibuSHIELD for HS and TibuSURE for SSc).
Expected impact: Establish clinical proof-of-concept and differentiation for the dual-pathway mechanism in autoimmune and inflammatory diseases.
Conducting preclinical, translational, and academic collaborative research to assess future clinical development strategies for crebankitug (ZB-168, targeting IL-7Rα) and torudokimab (ZB-880, targeting IL-33).
Expected impact: Identify optimal therapeutic indications and commercial potential for secondary pipeline assets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Exclusive global license to develop and commercialize tibulizumab (ZB-106), the company's flagship clinical asset.
Terms: Includes upfront payments, equity-in-lieu of cash, and potential future milestone and royalty obligations.
Exclusive global license to develop and commercialize crebankitug (ZB-168), expanding the company's dual-pathway immunology portfolio.
Terms: Subject to development, regulatory, and commercial milestone payments and royalties.